Trials / Active Not Recruiting
Active Not RecruitingNCT05511922
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
A Pharmacokinetic Subtrial in Adolescent Patients With Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- KalVista Pharmaceuticals, Ltd. · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KVD900 600 mg | KVD900 Tablet 600 mg (2 x 300 mg) |
| DRUG | Drug: KVD900 300 mg | KVD900 Tablet 300 mg |
Timeline
- Start date
- 2022-10-24
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2022-08-23
- Last updated
- 2025-07-18
Locations
61 sites across 17 countries: United States, Australia, Austria, Bulgaria, Canada, France, Germany, Greece, Israel, Japan, Netherlands, New Zealand, Romania, Slovakia, South Africa, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05511922. Inclusion in this directory is not an endorsement.